blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3297608

EP3297608 - COMBINATION HIV THERAPEUTIC [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.05.2023
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  10.06.2022
FormerGrant of patent is intended
Status updated on  24.02.2022
FormerExamination is in progress
Status updated on  24.04.2020
FormerRequest for examination was made
Status updated on  23.02.2018
FormerThe international publication has been made
Status updated on  02.12.2016
Most recent event   Tooltip09.02.2024Lapse of the patent in a contracting state
New state(s): IT		published on 13.03.2024  [2024/11]
Applicant(s)For all designated states
APHIOS CORPORATION
3-E Gill Street
Woburn, MA 01801 / US
[2018/13]
Inventor(s)01 / CASTOR, Trevor Percival
469 Mystic Street
Arlington, MA 02474 / US
 [2018/13]
Representative(s)Vossius, Corinna, et al
Corinna Vossius IP Group
Patent- und Rechtsanwaltskanzlei
Buchenstraße 17
82064 Straßlach-Dingharting / DE
[2022/28]
Former [2018/13]Vossius, Corinna
Corinna Vossius IP Group
Patent- und Rechtsanwaltskanzlei
Widenmayerstrasse 43
80538 München / DE
Application number, filing date16800598.123.05.2016
[2018/13]
WO2016US33766
Priority number, dateUS201562165444P22.05.2015         Original published format: US 201562165444 P
[2018/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016191363
Date:01.12.2016
Language:EN
[2016/48]
Type: A1 Application with search report 
No.:EP3297608
Date:28.03.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 01.12.2016 takes the place of the publication of the European patent application.
[2018/13]
Type: B1 Patent specification 
No.:EP3297608
Date:13.07.2022
Language:EN
[2022/28]
Search report(s)International search report - published on:US01.12.2016
(Supplementary) European search report - dispatched on:EP13.12.2018
ClassificationIPC:A61K9/14, A61K31/366, A61P31/18, A61K38/15, A61K31/167, A61K31/19, A61K31/325, A61K31/4045, A61K47/69, A61P31/12, A61K9/127, A61K31/20, A61K31/365, A61K47/68
[2019/03]
CPC:
A61K9/1271 (EP,US); A61K31/167 (EP,US); A61K31/19 (EP,US);
A61K31/20 (EP,US); A61K31/325 (EP,US); A61K31/365 (EP,US);
A61K31/4045 (EP,US); A61K38/15 (EP,US); A61K47/6851 (EP,US);
A61K47/6913 (EP,US); A61P31/12 (EP,US); Y10S977/773 (EP,US);
Y10S977/906 (EP,US); Y10S977/907 (EP,US) (-)
C-Set:
A61K31/167, A61K2300/00 (US,EP);
A61K31/20, A61K2300/00 (US,EP);
A61K31/365, A61K2300/00 (EP,US);
A61K31/4045, A61K2300/00 (US,EP)
Former IPC [2018/13]A61K9/14, A61K31/366, A61P31/18
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/13]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:KOMBINIERTES HIV-THERAPEUTIKUM[2018/13]
English:COMBINATION HIV THERAPEUTIC[2018/13]
French:THÉRAPEUTIQUE COMBINÉE CONTRE LE VIH[2018/13]
Entry into regional phase19.12.2017National basic fee paid 
19.12.2017Search fee paid 
19.12.2017Designation fee(s) paid 
19.12.2017Examination fee paid 
Examination procedure19.12.2017Examination requested  [2018/13]
19.12.2017Date on which the examining division has become responsible
25.09.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
20.11.2019Amendment by applicant (claims and/or description)
29.04.2020Despatch of a communication from the examining division (Time limit: M04)
20.08.2020Reply to a communication from the examining division
19.02.2021Despatch of a communication from the examining division (Time limit: M04)
05.05.2021Reply to a communication from the examining division
25.02.2022Communication of intention to grant the patent
02.06.2022Fee for grant paid
02.06.2022Fee for publishing/printing paid
02.06.2022Receipt of the translation of the claim(s)
Opposition(s)14.04.2023No opposition filed within time limit [2023/25]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
28.11.2019Request for further processing filed
28.11.2019Full payment received (date of receipt of payment)
Request granted
03.01.2020Decision despatched
The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
20.11.2019Request for further processing filed
20.11.2019Full payment received (date of receipt of payment)
Request granted
03.01.2020Decision despatched
Fees paidRenewal fee
29.05.2018Renewal fee patent year 03
28.05.2019Renewal fee patent year 04
18.05.2020Renewal fee patent year 05
25.05.2021Renewal fee patent year 06
09.05.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL13.07.2022
AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
ES13.07.2022
FI13.07.2022
HR13.07.2022
IT13.07.2022
LT13.07.2022
LV13.07.2022
MC13.07.2022
NL13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
[2024/11]
Former [2024/09]AL13.07.2022
AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
MC13.07.2022
NL13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/37]AL13.07.2022
AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SI13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/29]AL13.07.2022
AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/23]AT13.07.2022
CZ13.07.2022
DK13.07.2022
EE13.07.2022
ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SK13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/22]AT13.07.2022
CZ13.07.2022
DK13.07.2022
ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
PL13.07.2022
RO13.07.2022
RS13.07.2022
SE13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/21]DK13.07.2022
ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
PL13.07.2022
RS13.07.2022
SE13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/20]ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
PL13.07.2022
RS13.07.2022
SE13.07.2022
SM13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/12]ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
PL13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
GR14.10.2022
IS13.11.2022
PT14.11.2022
Former [2023/11]ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
PL13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
GR14.10.2022
PT14.11.2022
Former [2023/10]ES13.07.2022
FI13.07.2022
HR13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
GR14.10.2022
PT14.11.2022
Former [2023/09]ES13.07.2022
FI13.07.2022
LT13.07.2022
LV13.07.2022
NL13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
PT14.11.2022
Former [2023/08]ES13.07.2022
FI13.07.2022
LT13.07.2022
NL13.07.2022
RS13.07.2022
SE13.07.2022
NO13.10.2022
Former [2023/06]NL13.07.2022
Documents cited:Search[XYI]US2010166806  (CASTOR TREVOR PERCIVAL [US]) [X] 1-3,6,11 * claims 1-13 * * abstract * * paragraphs [0036] , [0037] * * figures 10,11; examples 9,10 * [Y] 1-15 [I] 4,5,7-10,12-15;
 [Y]US2010247620  (CASTOR TREVOR PERCIVAL [US]) [Y] 1-15 * claims 1-9 *;
 [Y]US2013156822  (CASTOR TREVOR PERCIVAL [US]) [Y] 1-15* claims 1-13 *;
 [XYI]WO2013165592  (VOLPE JOSEPH M [US]) [X] 1-3,11 * claims 1-30 * [Y] 1-15 [I] 4,5;
 [IY]  - MOISES PEREZ ET AL, "Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency", CURRENT HIV RESEARCH, NL, (20100901), vol. 8, no. 6, doi:10.2174/157016210793499312, ISSN 1570-162X, pages 418 - 429, XP055530197 [I] 1-15 * abstract * * table 1 * * figure 5 * * "Results", "Discussion" * [Y] 1-15

DOI:   http://dx.doi.org/10.2174/157016210793499312
International search[XY]US2010166806  (CASTOR TREVOR PERCIVAL [US]) [X] 1-3, 5-6, 11-13, 15-16, 24 * ; abstract; figure 10; paragraph [0028], [0037], [0046], [0050]; claim 13 * [Y] 4, 7, 9-10, 14, 17, 19-22, 25;
 [Y]WO2015066535  (UNIV YALE [US]) [Y] 7, 10, 17, 20, 22 * ; page 2, lines 10-20; page 42, lines 1-5; page 43, lines 15-20; page 69, lines 20-25 *;
 [Y]  - SCHLICHTER, LM et al., "Successful Treatment of Murine Melanoma with Bryostatin 1.", CANCER RESEARCH, (19910115), vol. 51, pages 682 - 687, XP055334037 [Y] 4, 14 * ; abstract; page 682, column 2, paragraph 4 *
 [Y]  - WINDBERGS, M et al., "Biodegradable Core-Shell Carriers for Simultaneous Encapsulation of Synergistic Actives.", Journal of the American Chemical Society, (20130430), vol. 135, pages 7933 - 7937, XP055334043 [Y] 9-10, 19-22, 25 * ; abstract; page 7934, column 1, paragraph 1; page 7934, figure 2a-b *

DOI:   http://dx.doi.org/10.1021/ja401422r
 [A]  - BANDYOPADHYAY, A et al., "The impact of nanoparticle ligand density on dendritic- cell targeted vaccines.", Biomaterials, (20110400), vol. 32, no. 11, pages 3094 - 3105, XP028145193 [A] 8, 18, 23 * ; abstract; page 2, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/j.biomaterials.2010.12.054
 [A]  - KATLAMA, C et al., "Barriers to a Cure: New concepts in targeting and eradicating HIV-1 reservoirs.", Lancet, (20130615), vol. 381, no. 9883, pages 2109 - 2117, XP055223928 [A] 8, 18, 23 * ; page 4, paragraph 3 *

DOI:   http://dx.doi.org/10.1016/S0140-6736(13)60104-X
 [A]  - WEISS, L et al., "Human immunodeficiency virus-driven expansion of CD 4+ CD 25+ regulatory T - cells, which suppress HIV-specific CD 4 T- cell responses in HIV-infected patients.", BLOOD, (20041115), vol. 104, no. 10, pages 3249 - 3256, XP055334049 [A] 8, 18, 23 * ; abstract *

DOI:   http://dx.doi.org/10.1182/blood-2004-01-0365
Examination   - MICHAEL KOVOCHICH ET AL, "Activation of Latent HIV Using Drug-Loaded Nanoparticles", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, (20110405), vol. 6, no. 4, doi:10.1371/JOURNAL.PONE.0018270, ISSN 1932-6203, pages 1 - 8, XP002720610

DOI:   http://dx.doi.org/10.1371/journal.pone.0018270
by applicantUS8637074
    - MICHAEL KOVOCHICH et al., "Activation of Latent HIV Using Drug-Loaded Nanoparticles", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, (20110405), vol. 6, no. 4, doi:10.1371/journal.pone.0018270, pages 1 - 8, XP002720610

DOI:   http://dx.doi.org/10.1371/journal.pone.0018270
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.